David Sourdive
Company: Cellectis
Job title: Co-founder, Executive Vice President CMC and Manufacturing
Seminars:
Utilising Advanced Genomic Engineering Methods to Streamline Engineered Cell Therapy Production 3:15 pm
Improving CAR and TCR transduction through novel non-viral editing techniques Leveraging CRISPR, nanoparticle or electroporation systems to simplify gene editing and decrease cost Incorporating non-viral engineering into established manufacturing processes to accelerate productionRead more
day: Day 1 - Track C - Mid
Displaying Clinical Allogeneic Persistence to Increase Accessibility 2:15 pm
Preventing immune-rejection to maintain a durable off-the-shelf therapy response Cloaking therapies to mediate host immune evasion Optimising donor screening to select a high quality starting materialRead more
day: Day 1 - Track B - Mid
Panel Discussion: Comparing Viral Vs Non-Viral Engineering Methods 12:30 pm
Reviewing engineering efficiencies of various methods to boost yield Assessing respective payloads of each system to identify cargo restrictions Exploring novel techniques including nanoparticle-based and electroporation to outline potentialRead more
day: Day 1 - Track A - AM